CINXE.COM

<!DOCTYPE html><html lang="en" class="h-100"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title> UCSF Glioma Trial → CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma</title><meta property="og:title" content="UCSF Glioma Trial: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma"><meta name="description" content="This Glioma and Malignant Neoplasm study at UCSF is now recruiting people ages 12 months to 30 years."><meta property="og:description" content="This Glioma and Malignant Neoplasm study at UCSF is now recruiting people ages 12 months to 30 years."><meta property="og:url" content="https://clinicaltrials.ucsf.edu/trial/NCT04870944"><link rel="canonical" href="https://clinicaltrials.ucsf.edu/trial/NCT04870944"><meta name="author" content="UCSF"><meta name="generator" content="edu.ucsf.ctsi.rt.trialfinder"><meta name="referrer" content="origin-when-cross-origin"><meta name="google-site-verification" content="JXe923j97sTSgp-6yxsCdd25Muv0wMNfDR27ba3ER8M"><meta name="msvalidate.01" content="4E5209CC6688B86BBDD2FE074176C029"><link rel="shortcut icon" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/favicon.png"><link rel="alternate" type="application/atom+xml" title="UCSF Clinical Trials" href="https://clinicaltrials.ucsf.edu/meta/feed.atom"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ucsf"><meta property="og:image" content="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/share-image.jpg"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/ucsf_identity/banners.css"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/css/bootstrap.min.css" integrity="sha256-L/W5Wfqfa0sdBNIKN9cG6QA5F2qx4qICmU2VgLruv9Y=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/coliff/bootstrap-rfs@4.3.1/bootstrap-rfs.css" media="screen and (max-width: 1200px)" integrity="sha256-DgOE2c1ekD0TaTyiCQuH2NdeiZ6VifYJdLdfDwq6C+U=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/animate.css@3.7.2/animate.min.css" integrity="sha256-PHcOkPmOshsMBC+vtJdVr5Mwb7r0LkSVJPlPrp/IMpU=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/font-awesome@4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/css/style.css"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/css/style-local.css"> <script src="https://polyfill-fastly.io/v3/polyfill.min.js?features=default%2CObject.assign%2CObject.entries%2CPromise%2CURLSearchParams%2CURL" crossorigin="anonymous" defer></script> <script src="https://cdn.jsdelivr.net/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-OUFW7hFO0/r5aEGTQOz9F/aXQOt+TwqI1Z4fbVvww04=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/readmore-js@2.2.1/readmore.min.js" integrity="sha256-ygz7RPJkJA9GMkV/1XKiK5GEfenXOdkEj2yhi8LRipU=" crossorigin="anonymous" defer></script> <script src="https://cdn.jsdelivr.net/jquery.validation/1.15.1/jquery.validate.min.js" integrity="sha256-uUVS/d3xM3l8YmucAkj1DeRt6U4Y+Xv3ePUgVVEVmVw=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/mailcheck@1.1.1/src/mailcheck.min.js" integrity="sha256-aAPNEz/OtzaNXAt4jf5P9xxwG8GvJ5owTS5BtGMELGs=" crossorigin="anonymous" defer></script><script src="https://www.google.com/recaptcha/api.js" defer></script> <script src="https://clinicaltrials.ucsf.edu/assets/js/app.js" defer></script><script>var google_analytics_live_mode=0;var google_analytics_id='UA-1142388-28';var google_analytics_hostname='clinicaltrials.ucsf.edu';if(google_analytics_id&&google_analytics_hostname&&window.location&&window.location.hostname&&window.location.hostname===google_analytics_hostname){google_analytics_live_mode=1}var google_analytics_js_url='https://www.google-analytics.com/analytics_debug.js';if(google_analytics_live_mode){google_analytics_js_url='https://www.google-analytics.com/analytics.js'}(function(c,h,e,b,f,a,d){c['GoogleAnalyticsObject']=f;c[f]=c[f]||function(){(c[f].q=c[f].q||[]).push(arguments)},c[f].l=1*new Date();a=h.createElement(e),d=h.getElementsByTagName(e)[0];a.async=1;a.src=b;d.parentNode.insertBefore(a,d)})(window,document,'script',google_analytics_js_url,'ga');if(!google_analytics_live_mode){}if(google_analytics_live_mode){ga('create',google_analytics_id,'auto')}else{ga('set','sendHitTask',null)}ga('require','outboundLinkTracker');ga('require','pageVisibilityTracker');ga('send','pageview');var s_opt={};s_opt['s_apid']='53G5XLK75T';s_opt['s_ixnm']='trials_ucsf';s_opt['s_ixky']='6e038166fd15da69c2ed075975c00816';s_opt['s_plac']=undefined;s_opt['s_mlti']=false;var _paq=window._paq=window._paq||[];_paq.push(['setTrackerUrl','https://clinicaltrials.ucsf.edu/action/t/l/']);_paq.push(['setSiteId','9']);_paq.push(['setCustomDimension',1,'trial\u002dpage']);_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);_paq.push(['enableHeartBeatTimer']);(function(){var a=document,g=a.createElement('script'),s=a.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.src='https://clinicaltrials.ucsf.edu/action/t/js/';s.parentNode.insertBefore(g,s)})();</script><script async src="https://cdn.jsdelivr.net/npm/autotrack@1.0.3/autotrack.js" integrity="sha256-MFv0PQKCj7HPlACiJTgQ+3rHnOSY1a510jcQGGwtemQ=" crossorigin="anonymous"></script><script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "WebSite", "publisher": { "@type": "MedicalOrganization", "name": "UCSF", "address": "San Francisco Bay Area", "url": "https://www.ucsf.edu/", "logo": "https://s2.googleusercontent.com/s2/favicons?domain_url=https%3A%2F%2Fwww.ucsf.edu%2F", "sameAs": [ "https://twitter.com/@ucsf" ] } } </script><meta name="ahrefs-site-verification" content="5f73483e1fea16c76799e8797bf1b843c1c0cda17921ee5e1670f98bd81223f4"></head><body class="trial-page bg-light d-flex flex-column"> <a id="skip-to-main-content" class="sr-only sr-only-focusable" href="#content">Skip to main content</a> <header id="header" class="mb-4"><div id="ucsf-banner-nav"><div class="container-fluid"><div class="top-header-container" style="max-width: 100%"><div><ul class="menu"><li class="first"><a href="https://www.ucsf.edu">University of California San Francisco</a></li><li><a href="https://www.ucsfhealth.org/">UCSF Medical Center</a></li><li><a href="https://www.ucsf.edu/search">Search UCSF</a></li><li><a href="https://www.ucsf.edu/about">About UCSF</a></li></ul></div></div></div></div><nav class="navbar navbar-expand-md navbar-light d-print"> <a class="navbar-brand" href="https://clinicaltrials.ucsf.edu/"> <img src="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/site-name.png" alt="UCSF Clinical Trials"> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbar--menu--primary-content" aria-controls="navbar--menu--primary-content" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-end" id="navbar--menu--primary-content"><ul class="navbar-nav"> <li class="nav-item" id="navbar--menu--home"> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/">Search</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/browse/" id="navbar--menu--browse-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Browse </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--browse-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/">All trials</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials for…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/healthy">Healthy volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/pediatric" title="Pediatric clinical trials, for people under age 18">People under 18</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/geriatric" title="Geriatric clinical trials, for people over age 65">People over 65</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials seeking…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/black" title="Trials that may be particularly relevant to Black volunteers"> Black volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/chinese" title="Trials that may be particularly relevant to Chinese volunteers"> Chinese volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/hmong" title="Trials that may be particularly relevant to Hmong volunteers"> Hmong volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/korean" title="Trials that may be particularly relevant to Korean volunteers"> Korean volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/latinx" title="Trials that may be particularly relevant to Latinx volunteers"> Latinx volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/lgbtqia" title="Trials that may be particularly relevant to LGBTQIA+ volunteers"> LGBTQIA+ volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/mena" title="Trials that may be particularly relevant to Middle Eastern or North African volunteers"> Middle Eastern or North African volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/native-hawaiian" title="Trials that may be particularly relevant to Native Hawaiian volunteers"> Native Hawaiian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/south-asian" title="Trials that may be particularly relevant to South Asian volunteers"> South Asian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/veteran" title="Trials that may be particularly relevant to Veteran volunteers"> Veteran volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/vietnamese" title="Trials that may be particularly relevant to Vietnamese volunteers"> Vietnamese volunteers</a> </div></li> <li class="nav-item" id="navbar--menu--equity" data-nosnippet> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/about/equity">Equity <span class="d-none d-xl-inline">in Research</span></a></a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/about/" id="navbar--menu--about-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> About <span class="d-none d-lg-inline">the site</span> </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--about-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/">About UCSF Clinical Trials</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/for-researchers">For Researchers</a> <div class="dropdown-divider"></div><div class="dropdown-header">Learn more in…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/chinese" data-nosnippet>Chinese</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/spanish" data-nosnippet>Spanish</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/vietnamese" data-nosnippet>Vietnamese</a> </div></li></ul></div> </nav><nav class="breadcrumb-and-search-bar navbar navbar-expand navbar-light d-print d-flex justify-content-between"> <div><ol class="breadcrumb navbar-text my-0 pl-1" itemscope="itemscope" itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucsf.edu/" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" id="navbar--breadcrumb--link-1"> Home <meta itemprop="name" content="UCSF Clinical Trials"> </a> <meta itemprop="position" content="1"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucsf.edu/glioma" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" aria-description="See all trials related to Glioma" id="navbar--breadcrumb--link-2"> <span itemprop="name">Glioma</span> Studies </a> <meta itemprop="position" content="2"></li><li class="active">This trial</li></ol><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/glioma", "name": "Glioma" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/malignant-neoplasm", "name": "Malignant Neoplasm" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/dipg", "name": "DIPG" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/lymphoma", "name": "Lymphoma" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/solid-neoplasm", "name": "Solid Neoplasm" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/bone-cancer", "name": "Bone Cancer" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/osteosarcoma", "name": "Osteosarcoma" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/recurrent-osteosarcoma", "name": "Recurrent Osteosarcoma" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/central-nervous-system-neoplasm", "name": "Central Nervous System Neoplasms" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/refractory-osteosarcoma", "name": "Refractory Osteosarcoma" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/central-nervous-system-tumor", "name": "Central Nervous System Tumor" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/solid-tumor", "name": "Solid Tumor" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/neoplasm", "name": "Neoplasms" } }] } </script></div> <div><div class="d-none d-md-block navbar-text"><form method="GET" action="https://clinicaltrials.ucsf.edu/" class="form-inline my-1" role="search"> <label class="sr-only" for="header-search--input">Search</label> <input id="header-search--input" name="q" type="text" class="form-control form-control-sm" placeholder="Search UCSF clinical trials" title="Search clinical trials at UCSF"> <input class="sr-only form-control-sm btn btn-sm btn-secondary" type="submit" value="Search trials"> </form></div></div> </nav></header><main id="content" class="mx-1 mx-md-0"> <div class="container-xl px-5"><div class="row"><div class="col-md-9 col-lg-8" role="main" id="main-column"><div id="summary" class="page-header show-jargon-definitions"><h1 id="summary--title"> CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma </h1><p class="h6 hide-long-content">a study on <span class="comma-list"><span class="comma-list-item"> <a href="../glioma">Glioma</a></span><span class="comma-list-item"> <a href="../malignant-neoplasm">Malignant Neoplasm</a></span><span class="comma-list-item"> <a href="../dipg">DIPG</a></span><span class="comma-list-item"> <a href="../lymphoma">Lymphoma</a></span><span class="comma-list-item"> <a href="../solid-neoplasm">Solid Neoplasm</a></span><span class="comma-list-item"> <a href="../bone-cancer">Bone Cancer</a></span><span class="comma-list-item"> <a href="../osteosarcoma">Osteosarcoma</a></span><span class="comma-list-item"> <a href="../recurrent-osteosarcoma">Recurrent Osteosarcoma</a></span><span class="comma-list-item"> <a href="../central-nervous-system-neoplasm">Central Nervous System Neoplasms</a></span><span class="comma-list-item"> <a href="../refractory-osteosarcoma">Refractory Osteosarcoma</a></span><span class="comma-list-item"> <a href="../central-nervous-system-tumor">Central Nervous System Tumor</a></span><span class="comma-list-item"> <a href="../solid-tumor">Solid Tumor</a></span><span class="comma-list-item"> <a href="../neoplasm">Neoplasms</a></span></span></p></div><div id="trial-details-container"><div id="key-points" class="trial-details-block"><div class="row"> <div class="col"><h2 class="sr-only h3">Summary</h2><dl id="key-points-bullets" class="row"><dt class="d-none d-sm-block col-sm-1 col-lg-2"> <i class="fa fa-user fa-lg fa-fw" aria-hidden="true"></i> <span class="sr-only">Eligibility</span></dt><dd class="col-12 col-sm-11 col-lg-10"> <strong>for people ages 12 months to 30 years</strong> (<a href="#eligibility">full criteria</a>) </dd><dt class="d-none d-sm-block col-sm-1 col-lg-2"> <i class="fa fa-map-marker fa-lg fa-fw" aria-hidden="true"></i> <span class="sr-only">Location</span></dt><dd class="col-12 col-sm-11 col-lg-10"> <a href="#location"> at San Francisco, California and other locations </a> </dd><dt class="d-none d-sm-block col-sm-1 col-lg-2"> <i class="fa fa-calendar fa-lg fa-fw" aria-hidden="true"></i> <span class="sr-only">Dates</span></dt><dd class="col-12 col-sm-11 col-lg-10"><div> study started <span itemscope itemtype="https://schema.org/WebPage"><time itemprop="dateCreated" datetime="2022-01-28">January 2022</time></span></div><div> completion around <time datetime="2026-12-31">December 2026</time></div><div itemscope itemtype="https://schema.org/WebPage" aria-hidden="true" class="d-none"><meta itemprop="datePublished" content="2021-05-04"></div></dd><dt class="d-none d-sm-block col-sm-1 col-lg-2"> <i class="fa fa-user-md fa-lg fa-fw" aria-hidden="true"></i> <span class="sr-only">Principal Investigator</span></dt><dd class="col-12 col-sm-11 col-lg-10 comma-list"> by <span class="pi-name comma-list-item"><span><a href="https://profiles.ucsf.edu/kieuhoa.vo" target="_blank" rel="noopener author" class="trial--link-to-pi-profile">Kieuhoa T. Vo</a></span></span></dd></dl></div> <div class="d-none d-md-block col-md-auto" id="pi-photos-block"><figure class="figure"><img class="pi-photo figure-img img-fluid rounded" src="https://researcherprofiles.org/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx?NodeID=175247" alt="Headshot of Kieuhoa T. Vo" loading="lazy"><figcaption class="figure-caption">Kieuhoa T. Vo</figcaption></figure></div></div></div><div id="description" class="trial-details-block"><h2 class="h3">Description</h2><div class="show-jargon-definitions"><h3 class="h4">Summary</h3><div class="hide-long-content"><p>This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with <a href="../solid-tumor" class="trial--link-to-condition-in-text">solid tumors</a>, including central nervous system (CNS) tumors or <a href="../lymphoma" class="trial--link-to-condition-in-text">lymphoma</a> that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.</p></div><h3 class="h4">Official Title</h3><p class="hide-long-content">A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma</p><h3 class="h4">Details</h3><div class="hide-long-content"><p>PRIMARY OBJECTIVES:</p><ol type="a"><li>To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of FACT complex-targeting curaxin CBL0137 (CBL0137) administered via infusion on Day 1 and Day 8 of a 21-day cycle to children with recurrent or <a href="../solid-tumor" class="trial--link-to-condition-in-text">refractory solid tumors</a>, including <a href="../central-nervous-system-tumor" class="trial--link-to-condition-in-text">CNS tumors</a> and <a href="../lymphoma" class="trial--link-to-condition-in-text">lymphoma</a>. (Phase 1 Dose Escalation) II. To preliminarily determine the antitumor effects as measured by objective response rate of CBL0137 in children with progressive/recurrent <a href="../glioma" class="trial--link-to-condition-in-text">diffuse intrinsic pontine glioma</a> (DIPG) and other H3 K27M-mutant diffuse midline gliomas. (Phase 2) III. To preliminarily determine the antitumor effects as measured by objective response rate or stable disease for at least 4 months of CBL0137 in children, adolescents and young adults with osteosarcoma. (Phase 2)</li></ol><p>SECONDARY OBJECTIVES:</p><ol type="a"><li>To preliminarily determine the antitumor effects of CBL0137 in children with refractory solid tumors and other CNS tumors, to the extent possible in the context of a Phase 1 study.</li></ol><p>II. To define and describe the toxicities of CBL0137 in children with recurrent or refractory solid tumors, including CNS tumors.</p><p>III. To characterize the pharmacokinetics of CBL0137 in children with recurrent or refractory solid tumors, including CNS tumors.</p><p>EXPLORATORY OBJECTIVES:</p><ol type="a"><li>To measure biologic marker FACT in tumor specimens with potential for correlation with disease response.</li></ol><p>II. To evaluate the effect of CBL0137 on immune response by measuring the effects on the interferon response pathway in peripheral blood mononuclear cells.</p><p>III. To preliminarily determine the effect of treatment with CBL0137 on overall survival of children with DIPG or other diffuse midline gliomas, H3 K27M-mutant, in comparison with historical controls.</p><p>OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.</p><p>Patients receive CBL0137 intravenously (IV) over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy at baseline, echocardiograph (ECHO) prior to cycle 1, and as clinically indicated undergo collection of blood samples throughout the trial.</p><p>After completion of study treatment, patients are followed up at 3, 6, 9, 12, 18, 24, 36, 48 and 60 months.</p></div><h3 class="h4">Keywords</h3><p class=" hide-long-content"><span> Diffuse Midline Glioma, H3 K27M-Mutant</span>, <span> Metastatic Malignant Neoplasm in the Central Nervous System</span>, <span> <a href="../glioma" class="trial--link-to-condition-in-text">Recurrent Diffuse Intrinsic Pontine Glioma</a></span>, <span> Recurrent Lymphoma</span>, <span> Recurrent Malignant <a href="../solid-neoplasm" class="trial--link-to-condition-in-text">Solid Neoplasm</a></span>, <span> <a href="../recurrent-osteosarcoma" class="trial--link-to-condition-in-text">Recurrent Osteosarcoma</a></span>, <span> Recurrent Primary Malignant Central Nervous System Neoplasm</span>, <span> <a href="../lymphoma" class="trial--link-to-condition-in-text">Refractory Lymphoma</a></span>, <span> Refractory Malignant Solid Neoplasm</span>, <span> <a href="../refractory-osteosarcoma" class="trial--link-to-condition-in-text">Refractory Osteosarcoma</a></span>, <span> Refractory Primary Malignant Central Nervous System Neoplasm</span>, <span> Lymphoma</span>, <span> Neoplasms</span>, <span> Glioma</span>, <span> Osteosarcoma</span>, <span> Diffuse Intrinsic Pontine Glioma</span>, <span> <a href="../central-nervous-system-neoplasm" class="trial--link-to-condition-in-text">Central Nervous System Neoplasms</a></span>, <span> Nervous System Neoplasms</span>, <span> Recurrence</span>, <span> Biospecimen Collection</span>, <span> Bone Marrow Aspirate</span>, <span> Bone Marrow Biopsy</span>, <span> Echocardiography</span>, <span> FACT Complex-targeting Curaxin CBL0137</span></p></div></div><div id="eligibility" class="trial-details-block show-jargon-definitions"><h2 class="h3">Eligibility</h2><div class="hide-long-content"><div class="row"><div class="col-12 col-lg-6"><h3 class="h4 mt-0"> <i class="fa fa-check-square-o" aria-hidden="true"></i> You can join if… </h3><div><p><strong>Open to people ages 12 months to 30 years</strong></p><ul><li>Parts A and B1: Patients must be >= 12 months and =< 21 years of age at the time of study enrollment</li><li>Part B2 (relapsed/refractory osteosarcoma): Patients must be >= 12 months and =< 30 years of age at the time of study enrollment</li><li>Patients must have had histologic verification of malignancy at original diagnosis or relapse, except in patients with diffuse intrinsic brain stem tumors, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers, including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG) <ul><li> Part A: Patients with relapsed or <a href="../solid-tumor" class="trial--link-to-condition-in-text">refractory solid tumors</a> or <a href="../lymphoma" class="trial--link-to-condition-in-text">lymphoma</a>, including patients with <a href="../central-nervous-system-tumor" class="trial--link-to-condition-in-text">CNS tumors</a> or known CNS <a href="../metastasis" class="trial--link-to-condition-in-text">metastases</a> (including untreated or progressive) are eligible</li><li> Part B1: Patients with progressive or recurrent DIPG (diagnosed by biopsy or imaging characteristics) and other H3 K27M-mutant <a href="../glioma" class="trial--link-to-condition-in-text">diffuse midline gliomas</a> previously treated with radiation therapy</li><li> Part B2: Patients with relapsed or <a href="../refractory-osteosarcoma" class="trial--link-to-condition-in-text">refractory osteosarcoma</a></li></ul></li><li>Part A: Patients must have either measurable or evaluable disease</li><li>Part B1 and B2: Patients must have measurable disease</li><li>Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life</li><li>Patients must have a performance status corresponding to Easter Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age. Patients must have a Karnofsky or Lansky score >= 50%</li><li>Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g., blood count criteria, the patient is considered to have recovered adequately <ul><li> Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive <ul><li> Solid tumor patients: >= 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)</li></ul></li><li> Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent</li><li> Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1</li><li> Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid. Patients with CNS tumors receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment</li><li> Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or 7 days for short acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur</li><li> Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)</li><li> Stem cell Infusions (with or without total body irradiation [TBI]): <ul><li> Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of <a href="../graft-versus-host-disease" class="trial--link-to-condition-in-text">graft versus host disease</a> (GVHD)</li><li> Autologous stem cell infusion including boost infusion: >= 30 days</li></ul></li><li> Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g., modified T cells, natural killer [NK] cells, dendritic cells, etc.)</li><li> Radiation therapy [XRT]/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation</li><li> Radiopharmaceutical therapy (e.g., radiolabeled antibody, I-131 metaiodobenzylguanidine [131I MIBG]): >= 42 days after systemically administered radiopharmaceutical therapy</li><li> Patients must not have received prior exposure to CBL0137</li></ul></li><li>For patients with solid tumors without known bone marrow involvement: <ul><li> Peripheral absolute neutrophil count (ANC) >= 1000/uL (performed within 7 days prior to enrollment unless otherwise indicated)</li><li> Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions). These patients will not be evaluable for hematologic toxicity. At least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study. If dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity</li></ul></li><li>For patients with solid tumors without known bone marrow involvement: <ul><li> Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) (performed within 7 days prior to enrollment unless otherwise indicated)</li><li> Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions). These patients will not be evaluable for hematologic toxicity. At least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study. If dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity</li></ul></li><li><p>Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m<sup>2</sup> or a creatinine based on age/gender as follows (performed within 7 days prior to enrollment unless otherwise indicated):</p><ul><li> Age: Maximum serum creatinine (mg/dL)</li><li> 1 to < 2 years: 0.6 (male); 0.6 (female)</li><li> 2 to < 6 years: 0.8 (male); 0.8 (female)</li><li> 6 to < 10 years: 1 (male); 1 (female)</li><li> 10 to < 13 years: 1.2 (male); 1.2 (female)</li><li> 13 to < 16 years: 1.5 (male); 1.4 (female)</li><li> >= 16 years: 1.7 (male); 1.4 (female)</li></ul></li><li>Patients with solid tumors: <ul><li> Bilirubin (sum of conjugated + unconjugated or total) =< 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment unless otherwise indicated)</li></ul></li><li>Patients with solid tumors: <ul><li> Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L (performed within 7 days prior to enrollment unless otherwise indicated)</li></ul></li><li>Shortening fraction of >= 27% by echocardiogram (performed within 7 days prior to enrollment unless otherwise indicated)</li><li>Ejection fraction of >= 50% by gated radionuclide study (performed within 7 days prior to enrollment unless otherwise indicated)</li><li>Corrected QT (QTC) < 480 msec (performed within 7 days prior to enrollment unless otherwise indicated)</li><li>Patients with <a href="../seizure" class="trial--link-to-condition-in-text">seizure disorder</a> may be enrolled if seizures well controlled without the use of enzyme-inducing anti-convulsant agents. Well controlled is defined by no increase in seizure frequency in the prior 7 days</li><li>Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5) resulting from prior therapy must be =< grade 2, with the exception of decreased tendon reflex (DTR). Any grade of DTR is eligible</li><li>Patients have consented to receive a central venous catheter prior to the administration of CBL0137. A central line is required for CBL0137 administration</li></ul></div></div><div class="col-12 col-lg-6"><h3 class="h4 mt-0"> <i class="fa fa-ban" aria-hidden="true"></i> You CAN'T join if... </h3><div><ul><li>Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies, OR because there is yet no available information regarding human fetal or teratogenic toxicities. <a href="../pregnancy" class="trial--link-to-condition-in-text">Pregnancy</a> tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two effective methods of birth control, including a medically accepted barrier or contraceptive method (e.g., male or female condom) for the duration of the study. Abstinence is an acceptable method of birth control</li><li>Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible. If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid</li><li>Patients who are currently receiving another investigational drug are not eligible</li><li>Patients who are currently receiving other anti-cancer agents are not eligible (except <a href="../leukemia" class="trial--link-to-condition-in-text">leukemia</a> patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)</li><li>Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial</li><li>Patients who are receiving drugs that are strong inducers or inhibitors of CYP3A4, CYP2B6 (e.g., carbamazepine) and CYP1A2 (e.g., ciprofloxacin, enoxacin, fluvoxamine, <a href="../smoking-cessation" class="trial--link-to-condition-in-text">smoking</a>) are not eligible. These agents are to be avoided for 7 days prior to the start of CBL0137 and for the duration of the protocol therapy. Sensitive substrates of CYP2D6 (e.g., atomoxetine, desipramine, dextromethorphan, eliglustat, nebivolol, nortriptyline, perphenazine, tolterodine, R-venlafaxine) should also be avoided for the duration protocol therapy</li><li>Patients who are receiving drugs associated with a known risk of Torsades de Pointes (TdP) are not eligible. Drugs associated with known risk of Torsades de Pointes (TdP) are to be avoided for 7 days prior to the start of CBL0137 and for duration of the protocol therapy</li><li>Patients with known <a href="../vascular-disease" class="trial--link-to-condition-in-text">peripheral vascular disease</a> are excluded</li><li>Patients with a history of pro-thrombotic disorder are not eligible</li><li>Patients who have an uncontrolled infection are not eligible</li><li>Patients who have received a prior solid organ transplantation are not eligible</li><li>Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible</li></ul></div></div></div></div></div><div id="location" class="trial-details-block"><h2 class="h3">Locations</h2><ul id="locations-list" class="hide-long-content "><li class="location location-is-institutional" itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">UCSF Medical Center-Mission Bay</span><wbr> <span class="badge badge-secondary">accepting new patients</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> San Francisco</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94158</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Children's Hospital Los Angeles</span><wbr> <span class="badge badge-secondary">accepting new patients</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> Los Angeles</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 90027</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li></ul></div><div id="pis" class="trial-details-block"><h2 class="h3">Lead Scientist <span class="d-none d-sm-inline">at UCSF</span></h2><ul class="pis-list--only-one-pi"><li class="pi"><span class="pi-name"> <strong> <a href="https://profiles.ucsf.edu/kieuhoa.vo" target="_blank" rel="noopener author" class="trial--link-to-pi-profile">Kieuhoa T. Vo</a> </strong> </span><br> Associate Professor, Pediatrics, School of Medicine. Authored (or co-authored) 26 research publications </li></ul></div><div id="details" class="trial-details-block"><h2 class="h3">Details</h2><dl class="row"><dt class="col-sm-3 text-sm-right">Status</dt><dd class="col-sm-9"> accepting new patients </dd><dt class="col-sm-3 text-sm-right">Start Date</dt><dd class="col-sm-9"><time datetime="2022-01-28">January 2022</time></dd><dt class="col-sm-3 text-sm-right">Completion Date</dt><dd class="col-sm-9"><time datetime="2026-12-31">December 2026</time> (estimated)</dd><dt class="col-sm-3 text-sm-right">Sponsor</dt><dd class="col-sm-9">Children's Oncology Group</dd><dt class="col-sm-3 text-sm-right">ID</dt><dd class="col-sm-9"> <a href="https://clinicaltrials.gov/ct2/show/NCT04870944" class="trial--link-to-clinicaltrials-gov" target="_blank" rel="noopener nofollow" title="ClinicalTrials.gov identifier">NCT04870944</a> </dd><dt class="col-sm-3 text-sm-right">Phase</dt><dd class="col-sm-9">Phase 1/2 research study</dd><dt class="col-sm-3 text-sm-right">Study Type</dt><dd class="col-sm-9">Interventional</dd><dt class="col-sm-3 text-sm-right">Participants</dt><dd class="col-sm-9">Expecting 95 study participants</dd><dt class="col-sm-3 text-sm-right">Last Updated</dt><dd class="col-sm-9"><span itemscope itemtype="https://schema.org/WebPage"><time itemprop="dateModified" datetime="2024-10-23">October 23, 2024</time></span></dd></dl></div><div id="faq" class="trial-details-block d-print-none" role="complementary"><h2 class="h3">Frequently Asked Questions</h2><ul><li><a href="../about/how-clinical-trials-work">How Do Clinical Trials Work?</a></li><li><a href="../about/what-to-expect">What to Expect</a></li><li><a href="../about/who-can-join">Who Can Join</a></li><li><a href="../about/our-researchers">Our Researchers</a></li></ul></div><div class="text-center my-3"> <a href="#" id="contact-button-end" class="btn btn-primary btn-lg d-none d-md-inline" data-toggle="modal" data-target="#contact-modal" aria-description="Are you interested? Contact us to learn more about joining this clinical trial"> <i class="fa fa-envelope mr-2" aria-hidden="true"></i> Contact us about this trial </a> </div></div> </div><div class="col-md-3 text-center offset-lg-1 d-none d-md-block d-print-none" id="secondary-column"> <div id="sidebar"> <a href="#" id="contact-button-sidebar" class="animated zoomIn btn btn-lg btn-block btn-primary mb-4" data-toggle="modal" data-target="#contact-modal" aria-description="Are you interested? Contact us to learn more about joining this clinical trial"> <span id="contact-button-sidebar--main-text" class="responsive-headline"> I’m interested<span class="d-none d-lg-inline">!</span></span> </a> <aside id="share-links"><h3 class="sr-only">Share study</h3><ul class="list-unstyled"><li class="hide-unless-mobile"> <a id="share-links--email" href="#" role="button" title="Share this trial by email" rel="nofollow"><i class="fa fa-envelope fa-2x" aria-hidden="true"><span class="sr-only">Share by email</span></i></a> </li><li> <a id="print-button-sidebar" href="#" role="button" title="Print this trial for my doctor" rel="nofollow"><i class="fa fa-print fa-2x" aria-hidden="true"><span class="sr-only">Print this trial</span></i></a> </li></ul></aside></div> </div></div> </div> <div id="contact-button-bottom-container" class="d-md-none d-print-none"> <a href="#" id="contact-button-bottom" class="animated fadeInDownBig btn btn-lg btn-block btn-primary d-print-none" data-toggle="modal" data-target="#contact-modal" aria-label="Are you interested? Contact us to learn more about joining this clinical trial"> I’m interested in this study! </a> </div> <div class="modal fade" id="contact-modal" tabindex="-1" role="dialog" aria-labelledby="contact-modal-label" aria-hidden="true"><div class="modal-dialog modal-dialog-scrollable" role="document"><div class="modal-content"><div class="modal-header"><h4 class="modal-title h5" id="contact-modal-label">Please contact me about this study</h4> <button type="button" class="close" data-dismiss="modal" aria-label="Close"> <span aria-hidden="true">×</span> </button> </div><div class="modal-body"> <form id="contact-form" class="form-horizontal" action="https://clinicaltrials.ucsf.edu/action/trial-contact/" method="POST"> <input type="hidden" name="Trial_NCT" value="NCT04870944"> <input type="hidden" name="Trial_Title" value="CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma"> <input type="hidden" name="Trial_Contact" value="53616c7465645f5f0a141e28323c46506be69b499b95fcd088659b5980f17692d9835d54eaea830731068ae4733f3b1b"> <div class="form-group row"> <label class="col-sm-3 col-form-label col-form-label-lg text-sm-right" for="contact-name">Name</label> <div class="col-sm-8 form-group--input-container"> <input name="Name" type="text" class="form-control form-control-lg" id="contact-name" placeholder="Your name" required pattern=".*\w\w.*" minlength="2" autocomplete="name"> </div></div><div class="form-group row"> <label class="col-sm-3 col-form-label col-form-label-lg text-sm-right" for="contact-email">Email</label> <div class="col-sm-8 form-group--input-container"> <input name="Email" type="email" class="form-control form-control-lg" id="contact-email" placeholder="Your email" required data-error="Invalid email address" autocomplete="email"> <div id="contact-email--suggestion" class="d-none small"> You typed <span id="contact-email--suggestion-original" class="text-monospace text-info font-weight-bold"></span>. Did you mean <span id="contact-email--suggestion-email" class="text-monospace text-info font-weight-bold"></span>? </div></div></div><div class="form-group row"> <label class="col-sm-3 col-form-label col-form-label-lg text-sm-right" for="contact-phone">Phone</label> <div class="col-sm-8 form-group--input-container"> <input name="Phone" type="tel" class="form-control form-control-lg" id="contact-phone" placeholder="Your phone (optional)" pattern=".*\d.*\d.*\d.*\d.*\d.*\d.*\d.*\d.*" minlength="8" autocomplete="tel"> </div></div><div class="form-group row"> <label class="col-sm-3 col-form-label col-form-label-lg text-sm-right">Are you human?</label> <div class="col-sm-8 form-group--input-container"><div class="g-recaptcha" id="contact-recaptcha-captcha" data-sitekey="6LfpryUTAAAAAKT_A9vSYllUZW9fS3l-SzN_dzU2"></div><p class="small mb-0">This step makes sure spammers don’t flood our inbox</p></div></div><div class="form-group row"><div class="offset-sm-3 col-sm-8"> <button type="submit" class="btn btn-primary btn-lg">Send to study team</button> </div></div></form><p class="small">We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.</p></div> </div></div></div><div class="modal fade" id="contact-thank-you-modal" tabindex="-1" role="dialog" aria-hidden="true" aria-labelledby="contact-modal-label"><div class="modal-dialog" role="document"><div class="modal-content"><div class="modal-header"> <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">×</span><span class="sr-only">Close</span></button> <h4 class="modal-title h5" id="contact-thank-you-modal-label">Thank you!</h4></div><div class="modal-body"><p>The study team should get back to you in a few business days.</p><p>You will also receive an email with next steps. Check your junk/spam folder if needed.</p><p>If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT04870944.</p></div><div class="modal-footer"> <button type="button" class="btn btn-primary" data-dismiss="modal">OK</button> </div></div></div></div> <script type="application/ld+json"> [{"@context":"https://schema.org/","@type":"MedicalTrial","additionalType":"Product","alternateName":"A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma","code":{"@type":"MedicalCode","codeValue":"NCT04870944","codingSystem":"ClinicalTrials.gov"},"description":"This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.","healthCondition":[{"@type":"MedicalCondition","name":"Glioma"},{"@type":"MedicalCondition","name":"Malignant Neoplasm"},{"@type":"MedicalCondition","name":"DIPG"},{"@type":"MedicalCondition","name":"Lymphoma"},{"@type":"MedicalCondition","name":"Solid Neoplasm"},{"@type":"MedicalCondition","name":"Bone Cancer"},{"@type":"MedicalCondition","name":"Osteosarcoma"},{"@type":"MedicalCondition","name":"Recurrent Osteosarcoma"},{"@type":"MedicalCondition","name":"Central Nervous System Neoplasms"},{"@type":"MedicalCondition","name":"Refractory Osteosarcoma"},{"@type":"MedicalCondition","name":"Central Nervous System Tumor"},{"@type":"MedicalCondition","name":"Solid Tumor"},{"@type":"MedicalCondition","name":"Neoplasms"}],"name":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","sameAs":"https://clinicaltrials.gov/study/NCT04870944","sponsor":[{"@type":"Organization","name":"Children's Oncology Group"},{"@context":"https://schema.org/","@type":"Person","affiliation":{"@type":"Organization","name":"UCSF"},"description":"Associate Professor, Pediatrics, School of Medicine. Authored (or co-authored) 26 research publications","image":"https://researcherprofiles.org/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx?NodeID=175247","isicV4":"7210","jobTitle":"Principal Investigator","name":"Kieuhoa T. Vo","url":"https://profiles.ucsf.edu/kieuhoa.vo"}],"status":"https://schema.org/Recruiting","studyLocation":[{"@type":"AdministrativeArea","address":{"@type":"PostalAddress","addressCountry":"United States","addressLocality":"San Francisco","addressRegion":"California","postalCode":"94158"},"name":"UCSF Medical Center-Mission Bay"}],"studySubject":[{"@type":"MedicalEntity","name":"Diffuse Midline Glioma, H3 K27M-Mutant"},{"@type":"MedicalEntity","name":"Metastatic Malignant Neoplasm in the Central Nervous System"},{"@type":"MedicalEntity","name":"Recurrent Diffuse Intrinsic Pontine Glioma"},{"@type":"MedicalEntity","name":"Recurrent Lymphoma"},{"@type":"MedicalEntity","name":"Recurrent Malignant Solid Neoplasm"},{"@type":"MedicalEntity","name":"Recurrent Osteosarcoma"},{"@type":"MedicalEntity","name":"Recurrent Primary Malignant Central Nervous System Neoplasm"},{"@type":"MedicalEntity","name":"Refractory Lymphoma"},{"@type":"MedicalEntity","name":"Refractory Malignant Solid Neoplasm"},{"@type":"MedicalEntity","name":"Refractory Osteosarcoma"},{"@type":"MedicalEntity","name":"Refractory Primary Malignant Central Nervous System Neoplasm"},{"@type":"MedicalEntity","name":"Lymphoma"},{"@type":"MedicalEntity","name":"Neoplasms"},{"@type":"MedicalEntity","name":"Glioma"},{"@type":"MedicalEntity","name":"Osteosarcoma"},{"@type":"MedicalEntity","name":"Diffuse Intrinsic Pontine Glioma"},{"@type":"MedicalEntity","name":"Central Nervous System Neoplasms"},{"@type":"MedicalEntity","name":"Nervous System Neoplasms"},{"@type":"MedicalEntity","name":"Recurrence"},{"@type":"MedicalEntity","name":"Biospecimen Collection"},{"@type":"MedicalEntity","name":"Bone Marrow Aspirate"},{"@type":"MedicalEntity","name":"Bone Marrow Biopsy"},{"@type":"MedicalEntity","name":"Echocardiography"},{"@type":"MedicalEntity","name":"FACT Complex-targeting Curaxin CBL0137"}],"trialDesign":["https://schema.org/MultiCenterTrial"]},{"@type":"Offer","availability":"https://schema.org/InStock","availabilityEnds":"2026-12-31","availabilityStarts":"2022-01-28","hasAdultConsideration":[],"name":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","price":0,"priceCurrency":"USD","sku":"NCT04870944","validFrom":"2022-01-28","validThrough":"2026-12-31"},{"@context":"https://schema.org/","@type":"Place","address":{"@type":"PostalAddress","addressCountry":"United States","addressLocality":"San Francisco","addressRegion":"California","postalCode":"94158"},"name":"UCSF Medical Center-Mission Bay"},{"@context":"https://schema.org/","@type":"Person","affiliation":{"@type":"Organization","name":"UCSF"},"description":"Associate Professor, Pediatrics, School of Medicine. Authored (or co-authored) 26 research publications","image":"https://researcherprofiles.org/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx?NodeID=175247","isicV4":"7210","jobTitle":"Principal Investigator","name":"Kieuhoa T. Vo","url":"https://profiles.ucsf.edu/kieuhoa.vo"}] </script> </main><footer class="mt-auto" role="contentinfo" data-nosnippet><div id="ucsf--footer--body"><div class="container" data-nosnippet><div class="row mb-1 d-print-none"><div class="col-12 text-center text-md-left"> We use cookies to operate our website, analyze performance, and improve your experience on our site. <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Learn more.</a> </div></div><div class="row"><div class="col-md-6 text-center text-md-left"><p class="my-0"> © The Regents of the University of California </p></div><div class="col-md-6 text-center text-md-right pt-3 pt-md-0"> <a href="https://websites.ucsf.edu/digital-accessibility" target="_blank">Accessibility</a> <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Privacy Policy</a> <a href="https://websites.ucsf.edu/website-terms-use" target="_blank">Terms of Use</a> </div></div></div></div></footer><script>(function(){var b=document.createElement('script');b.type='text/javascript';b.async=true;b.src='//siteimproveanalytics.com/js/siteanalyze_8343.js';var a=document.getElementsByTagName('script')[0];a.parentNode.insertBefore(b,a)})();</script></body></html>